Reliability, validity, and sensitivity of Japanese version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument: application to efficacy assessment of intravenous immunoglobulin administration - Matsuda, Kazuki M; Sugimoto, Eiki; Ako, Yoshiaki; Kitamura, Marie; Miyahara, Mai; Kotani, Hirohito; Norimatsu, Yuta; Hisamoto, Teruyoshi; Kuzumi, Ai; Fukasawa, Takemichi; Sato, Shinichi; Yoshizaki, Ayumi (medRxiv, 2023)
Objective This study aimed to develop and assess the reliability, validity, and sensitivity of Japanese version of the University of California Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (GIT) Instrument 2.0 (the GIT score), as an evaluation tool for GIT symptoms in systemic sclerosis (SSc).Methods Japanese version of the GIT score was constructed using the forward-backward method. The reliability and validity of this instrument were evaluated in a cohort of 38 SSc patients. Correlation analysis was conducted to assess the relationship between the GIT score and existing patient-reported outcome measures. Additionally, the sensitivity of the GIT score was examined by comparing GIT scores before and after intravenous immunoglobulin (IVIG) administration in 10 SSc-myositis overlap patients, as IVIG has recently demonstrated effectiveness in alleviating GIT symptoms of SSc.Results Japanese version of the GIT score exhibited internal consistency and a significant association with the Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease. Furthermore, the total GIT score, as well as the reflux and distention/bloating subscales, displayed moderate correlations with the EQ-5D pain/discomfort subscale, Short Form-36 body pain subscale, and its physical component summary. Notably, following IVIG treatment, there was a statistically significant reduction in the total GIT score and most of the subscales.Conclusion We firstly validated Japanese version of the GIT score in Japanese SSc patients in real-world clinical settings. This instrument holds promise for application in future clinical trials involving this patient population.What is already known about this subject?Khanna et al. developed the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract (GIT) Instrument (the GIT score) to assess patient-reported GIT symptoms in individuals with systemic sclerosis (SSc).What does this study add?We have developed and established the reliability, validity, and sensitivity of the Japanese version of the GIT score in cohorts of Japanese individuals with SSc.How might this impact on clinical practice?This tool can effectively evaluate GIT manifestations in Japanese SSc patients in routine clinical settings, and potentially in clinical trial contexts.Competing Interest StatementTF and AY belong to the Social Cooperation Program, Department of Clinical Cannabinoid Research, supported by Japan Cosmetic Association and Japan Federation of Medium and Small Enterprise Organizations. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by The University of Tokyo Ethical Committee (Approval Number 0695).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.